Cover Image
市場調查報告書

間歇性跛行的開發中產品分析

Intermittent Claudication - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 200461
出版日期 內容資訊 英文 51 Pages
訂單完成後即時交付
價格
Back to Top
間歇性跛行的開發中產品分析 Intermittent Claudication - Pipeline Review, H2 2016
出版日期: 2016年07月13日 內容資訊: 英文 51 Pages
簡介

「跛行」(Claudication)語源來自拉丁語中「拖」一詞,是指運動中(特別步行中)所發生的痙攣性下肢疼痛。這個疼痛是由於(動脈閉塞造成的)下肢缺血而產生。此外「間歇」(Intermittent)則代表疼痛會時有時無。間歇性跛行是末稍動脈疾病(PAD)中最常見的症狀,PAD中成人有1/3到半數會有此症狀。其症狀有疼痛和痙攣,倦怠感,或是每次運動時都會產生的不特定不適感等。但只是站立時並不會產生不適感。此外只要休息,大部分症狀都會緩解。最初時只有在走上坡路、快走、步行長距離才會出現症狀。

本報告提供治療全球各國的間歇性跛行治療用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)的發展情形),最新的產業趨勢等調查。

簡介

  • 調查範圍

間歇性跛行概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的開發企業

  • Cytokinetics, Inc.
  • DNAVEC Corporation
  • Genovate Biotechnology Co., LTD.
  • 興和
  • LTT Bio-Pharma Co., Ltd.
  • Nuo Therapeutics, Inc.
  • Pluristem Therapeutics Inc.
  • Rigel Pharmaceuticals, Inc.
  • 大正富山醫藥品

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ALD-301
  • alprostadil
  • cilostazol CR
  • CK-2066260
  • DVC1-0101
  • ecraprost
  • K-134
  • LT-0101
  • R-118
  • Stem Cell Therapy for Cardiovascular Deseases
  • tirasemtiv

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8221IDB

Summary

Global Markets Direct's, 'Intermittent Claudication - Pipeline Review, H2 2016', provides an overview of the Intermittent Claudication pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Intermittent Claudication, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Intermittent Claudication and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Intermittent Claudication
  • The report reviews pipeline therapeutics for Intermittent Claudication by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Intermittent Claudication therapeutics and enlists all their major and minor projects
  • The report assesses Intermittent Claudication therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Intermittent Claudication

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Intermittent Claudication
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Intermittent Claudication pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Intermittent Claudication Overview
  • Therapeutics Development
    • Pipeline Products for Intermittent Claudication - Overview
  • Intermittent Claudication - Therapeutics under Development by Companies
  • Intermittent Claudication - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Intermittent Claudication - Products under Development by Companies
  • Intermittent Claudication - Companies Involved in Therapeutics Development
    • ID Pharma Co., Ltd.
    • Kowa Company, Ltd.
    • Nuo Therapeutics, Inc.
    • Pluristem Therapeutics Inc.
  • Intermittent Claudication - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ALD-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DVC-10101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • K-134 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LT-0101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PLX-PAD - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Intermittent Claudication - Dormant Projects
  • Intermittent Claudication - Discontinued Products
  • Intermittent Claudication - Product Development Milestones
    • Featured News & Press Releases
      • May 16, 2016: Pluristem Completes Enrollment of 150 Patients in Phase II Intermittent Claudication Trial
      • Aug 17, 2015: Pluristem Granted U.S. Patent for Production Methods and Use of Placental Cell Therapy in a Range of Indications
      • Nov 13, 2013: Pluristem Receives Regulatory Approval to Extend Its Phase II Study of PLX-PAD Cells in the Treatment of Intermittent Claudication to South Korea
      • Oct 02, 2013: Pluristem Receives Israeli Ministry of Health Approval to Expand Its Phase II Clinical Trial in Intermittent Claudication to Israel
      • Sep 16, 2013: FDA Lifts Clinical Hold of Pluristem's Phase II Intermittent Claudication Study
      • Jul 08, 2013: Pluristem's South Korean Partner Files IND With Korean FDA for PLX Cells
      • Jun 04, 2013: Pluristem To Receive Clinical-hold Notice From FDA For US Phase II Intermittent Claudication Study
      • Jan 15, 2013: Pluristem Receives Approval To Expand Phase II Clinical Trial In Intermittent Claudication To Germany
      • Aug 23, 2012: Pluristem Commences Phase II Clinical Trial For Intermittent Claudication Using PLX Cells
      • Aug 13, 2012: Pluristem Moves Intermittent Claudication Indication Forward in Germany Through Collaboration With Cato Research
      • Jul 18, 2012: Pluristem Partners With CPC Clinical Research For Peripheral Artery Disease Study
      • Apr 17, 2012: Pluristem Receives FDA Clearance For Phase II Clinical Trial In Intermittent Claudication
      • Jan 11, 2012: Kowa Initiates Japan Phase IIb Clinical Trials Of Anti-Platelet Agent K-134
      • Dec 02, 2011: Kowa Releases Japan Phase IIb Clinical Trials Data Of Anti-Platelet Agent, K-134
      • Nov 10, 2011: Kowa Announces Efficacy And Safety Of K-134 For Treatment Of Intermittent Claudication In AHA 2011
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Intermittent Claudication, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Intermittent Claudication - Pipeline by ID Pharma Co., Ltd., H2 2016
  • Intermittent Claudication - Pipeline by Kowa Company, Ltd., H2 2016
  • Intermittent Claudication - Pipeline by Nuo Therapeutics, Inc., H2 2016
  • Intermittent Claudication - Pipeline by Pluristem Therapeutics Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Intermittent Claudication - Dormant Projects, H2 2016
  • Intermittent Claudication - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Intermittent Claudication, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top